UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $6.20 Million Position in Vericel Co. (NASDAQ:VCEL)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Vericel Co. (NASDAQ:VCEL - Free Report) by 17.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 112,837 shares of the biotechnology company's stock after acquiring an additional 16,466 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.23% of Vericel worth $6,196,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Louisiana State Employees Retirement System grew its stake in Vericel by 0.8% in the fourth quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company's stock valued at $1,312,000 after purchasing an additional 200 shares in the last quarter. Proficio Capital Partners LLC acquired a new position in Vericel during the fourth quarter valued at approximately $956,000. Empowered Funds LLC bought a new position in shares of Vericel in the fourth quarter valued at approximately $261,000. KBC Group NV lifted its stake in shares of Vericel by 82.5% in the fourth quarter. KBC Group NV now owns 2,707 shares of the biotechnology company's stock worth $149,000 after buying an additional 1,224 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Vericel by 1.2% in the fourth quarter. Bank of New York Mellon Corp now owns 309,372 shares of the biotechnology company's stock worth $16,988,000 after buying an additional 3,700 shares during the last quarter.

Insider Buying and Selling at Vericel

In other Vericel news, CEO Dominick Colangelo sold 26,592 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $45.78, for a total value of $1,217,381.76. Following the transaction, the chief executive officer now directly owns 259,997 shares in the company, valued at approximately $11,902,662.66. This trade represents a 9.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.20% of the company's stock.

Vericel Stock Up 3.8%

VCEL traded up $1.60 during trading on Wednesday, reaching $43.17. 549,264 shares of the company's stock were exchanged, compared to its average volume of 416,970. Vericel Co. has a fifty-two week low of $37.39 and a fifty-two week high of $63.00. The company has a market capitalization of $2.17 billion, a P/E ratio of 719.62 and a beta of 1.31. The business has a 50 day moving average price of $41.31 and a 200 day moving average price of $50.42.

Vericel (NASDAQ:VCEL - Get Free Report) last announced its earnings results on Thursday, May 8th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.14). Vericel had a net margin of 1.56% and a return on equity of 1.48%. The business had revenue of $52.60 million during the quarter, compared to analyst estimates of $53.86 million. During the same quarter last year, the business posted ($0.08) earnings per share. The business's quarterly revenue was up 2.6% compared to the same quarter last year. As a group, research analysts forecast that Vericel Co. will post 0.14 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on VCEL. Wall Street Zen lowered Vericel from a "hold" rating to a "sell" rating in a report on Monday, May 12th. Truist Financial lowered their price objective on shares of Vericel from $61.00 to $51.00 and set a "buy" rating on the stock in a research note on Friday, April 11th. Stephens reiterated an "overweight" rating and set a $67.00 target price on shares of Vericel in a research note on Thursday, May 22nd. Finally, HC Wainwright reissued a "buy" rating and issued a $60.00 price target on shares of Vericel in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $61.14.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.